From India to the US: Why Atorvastatin Is Raising Safety Alarms

A large-scale recall of atorvastatin, one of the world’s most widely prescribed cholesterol-lowering drugs, has been issued by Ascend Laboratories in the United States. The recall, classified as Class II by the US Food and Drug Administration (FDA), affects over 142,000 bottles and could impact hundreds of thousands of patients dependent on statins to manage heart disease risk.

Reason Behind the Recall

The recall was triggered after quality checks revealed that certain batches of atorvastatin tablets failed to dissolve properly. This flaw prevents the drug from being effectively absorbed by the body, reducing its ability to lower LDL (“bad”) cholesterol. The affected batches were produced between November 2024 and September 2025 by Alkem Laboratories in India. Though the defect is unlikely to cause immediate harm, it could elevate long-term risks of heart attacks and strokes among patients.

Scope and Impact of the Issue

Atorvastatin, marketed under both the brand name Lipitor and its generic versions, is taken daily by more than 29 million Americans. It remains the top-selling cholesterol drug globally, with over 115 million prescriptions annually. The recall affects bottles containing 90, 500, or 1,000 tablets, each distributed by Ascend Laboratories, whose National Drug Code (NDC) prefix is 67877. The FDA has advised healthcare providers to identify and isolate the affected batches to prevent further distribution.

Manufacturing Oversight and Global Supply Chain Risks

The incident has renewed scrutiny of pharmaceutical manufacturing standards, particularly for drugs produced overseas. Many global generic medicines are now made in India and China, where inspection processes have faced disruption and delays. Experts note that the COVID-19 pandemic exacerbated these oversight gaps, as regulatory agencies suspended on-site inspections. Recent quality lapses, including similar dissolution failures in other drugs, underscore the urgent need for stricter compliance and transparent monitoring systems.

Exam Oriented Facts

• Ascend Laboratories recalled 142,000 bottles of generic atorvastatin in September 2025.
• The recall was classified as Class II by the US FDA due to poor tablet dissolution.
• Atorvastatin, the generic of Lipitor, is used by over 29 million Americans.
• The affected batches were manufactured by Alkem Laboratories in India.

Advice for Patients and Next Steps

Doctors advise patients not to stop taking atorvastatin abruptly without consulting a healthcare provider. Pharmacists can verify whether specific prescriptions are part of the recall by checking for “MFG Ascend” or “MFR Ascend” on labels. The FDA encourages consumers to report issues through its MedWatch programme. Until international inspection systems are strengthened, public vigilance and transparent reporting remain key to ensuring drug quality and patient safety worldwide.

High dose statins can increase osteoporosis risk finds Annals of the Rheumatic Diseases study

A higher dose of statins, the cholesterol-lowering drug, could increase the risk of osteoporosis,  a recent has found. However, at low doses statins provide protection against bone resorption.
According to the study, whether statins decrease or increase the risk of osteoporosis is dependent on their dosage. At low doses, statins provide protection against bone resorption. However, the higher the dosage of statins greater is the risk of osteoporosis. In short, osteoporosis is underrepresented in low-dose and over-represented in high-dose statin treatment. Findings are based on an analysis of millions of patient data.

Osteoporosis is one of the most commonly occurring metabolic bone disorders. It is characterised by decreased bone mineral density (BMD) in which bones become weak and brittle. This increases the bone fragility making it susceptible to fracture.

Statins are cholesterol-lowering drugs that help the heart and brain by preventing artery plaques- buildups of cholesterol, calcium and other substances in blood vessels-- from blocking blood flow and causing a heart attack or stroke. They are among the most prescribed drugs worldwide.

Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Researchers conducted the study to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.

Statins inhibit the synthesis of cholesterol from the liver. This lowers blood cholesterol. However, cholesterol is crucially important for many processes in the body. Among other things, it is a basic building block for the production of sex hormones such as estradiol and testosterone.

For the investigation, the researchers used Big Data. They obtained access to the health data of more than 7.9 million Australians between 2006-2007. From this big data set the patients who regularly took statins for at least one year were filtered out. The researchers also calculated the daily dosage of statins and formed different dosage groups. In a further step, the interdisciplinary team filtered out osteoporosis diagnoses.

Key findings of the study include-
* statin treatment was associated with an over-representation of diagnosed osteoporosis compared with controls.
* there was a highly non-trivial dependence of statin dosage with the ORs of osteoporosis.
* Osteoporosis was underrepresented in low-dose statin treatment ) 0-10mg per day) including lovastatin, pravastatin, simvasatin and rosuvastatin.

The exceeding of the 40 mg threshold for simvastatin and the exceeding of a 20 mg threshold for atorastatin and for rosuvastatin was related to an over-representation of osteoporosis.

We know that low concentrations of sex hormones- especially the drop in estrogen levels during menopause-- are the main cause for the increase of osteoporosis in women, explains a Dr.  There is a similar relationship between bone density and testosterone. We were interested in whether the inhibition of cholesterol production by statins has an effect on bone formation and whether there could be a dose-response relationship.

In the lower dose groups, there were fewer osteoporosis cases than expected, points out the Dr. At doses up to 10mg of the statins lovastatin, pravastatin, simvastatin or rosuvastatin, the scientists found fewer osteoporosis diagnoses compared to patients without statin therapy. With doses of 20 mg, and more, however,  this seems to turn. We found more osteoporosis cases in patients treated with simvastatin, atorvastatin and rosuvastatin than expected, explains the Dr. The higher the dosage, the stronger the effect.

In earlier, joint studies we saw how helpful large data sets can be to examine open medical questions, says the leader of the study. The combination of medical expertise with our knowledge in big data analysis makes completely new insights possible. According to the researcher, the newly discovered correlation between statin therapy and osteoporosis risk should now be investigated in clinical studies.

With such results, we're coming closer to truly personalised and individualised medicine, maintains the Dr. We can now advise high-risk osteoporosis patients undergoing statin therapy to have their bone metabolism regularly monitored.

We propose that monitoring high-risk patients, that is postmenopausal female patients under high-dosage statin therapy, might be useful in order to offer individual therapy to prevent or treat osteoporosis. This, larger and prospective studies with a focus on dosages of statins should be conducted in order to clarify the relationship with osteoporosis, concluded the authors.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   
https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement   

Turmeric Is Just as Effective as These Drugs.

You are probably aware that turmeric is one of the most potent superfoods you could possibly get your hands on. But did you know that turmeric is actually roughly as potent as many kinds of medication? Keep reading to discover what kinds of medication can possibly be replaced or supplemented by turmeric:

Lipitor/Atorvastatin (cholesterol medication)
A 2008 study revealed that a standardized preparation of curcuminoids from turmeric had very similar effects to atorvastatin (trade name Lipitor) when it came to treating endothelial dysfunction, a driver for atherosclerosis. It was also associated with reductions in oxidative stress and inflammation in type 2 diabetic patients.

Aspirin (blood thinner)
Research shows that curcumin has even more anti-platelet and prostacyclin modulating effects than aspirin. This goes to show that it could be useful to patients prone to vascular thrombosis, who often require anti-arthritis therapy.

Corticosteroids (steroid medications)
Numerous studies have found that turmeric can be just as effective as many kinds of steroids. One found that the curcumin found within turmeric compared favorably to steroids used to treat the inflammatory eye disease known as anterior uveitis. Other studies also found that chemicals found within turmeric are just as effective as steroidal drugs that tackle lung ischemia-reperfusion injuries and those that protect injuries caused by lung transplants.

Prozac/Fluoxetine & Imipramine (antidepressants)
A 2011 study  showed us that curcumin also compares favorably to both Imipramine as well as Prozac/Fluoxetine when it comes to tackling the root causes of depression.

Anti-inflammatory Drugs
Curcumin has also been found to be an effective alternative to a whole host of anti-inflammatory drugs. These include ibuprofen, aspirin, phenylbutazone, naproxen, sulindac, dexamethasone, celecoxib, indomethacin, diclofenac, and tamoxifen, particularly when it comes to exerting anti-inflammatory and anti-proliferative activity against tumor cells.

Oxaliplatin (a chemotherapy drug)
A 2007 study concluded that curcumin also compares favorably with oxaliplatin as an antiproliferative agent in colorectal cell lines, which is certainly good news for any patients who are undergoing chemotherapy.

Metformin (diabetes drug)
Curcumin has also been touted as being highly valuable in the treatment of diabetes. One study found that it suppresses gluconeogenic gene expression (which suppresses glucose production in the liver) in hepatoma cells, while simultaneously activating AMPK (which increases glucose uptake). What's more, the researchers actually discovered that curcumin is between 500 and 100,000 times more powerful than metformin in activating AMPK and its downstream target acetyl-CoA carboxylase (ACC).

THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.                                                                                                                                                                                                       PS- THOSE INTERESTED IN RECIPES ARE FREE TO  VIEW MY BLOG-                                                                                           https://gseasyrecipes.blogspot.com/   

FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG-                                                                                          https:// kneereplacement-stickclub.blogspot.com/                              

FOR CROCHET DESIGNS                                                                                                                                                                                                                                 https://gscrochetdesigns.blogspot.com